Fig. 4

Mean change from baseline in JSN Subscore in the DMARD-IR population. Data are as observed in individual studies and estimated with meta-analysis. Solid line represents the mean estimate for a given treatment arm and the dashed lines show the corresponding 95 % credible interval. DMARD-IR: patient population with moderate-to-severe rheumatoid arthritis with a history of inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) who are currently treated with one (other) non-biologic DMARD; JSN: Joint Space Narrowing; MTX: methotrexate